Teva fined 463 million euros for blocking rival MS drug launch

31 October 2024

The European Union's antitrust enforcer hit Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA) with a 463 million-euro ($502 million) fine Thursday for launching a smear campaign against a rival multiple sclerosis drug and misusing the patent system to thwart the competitor's attempt to entering the market.

The European Commission said that Teva's abusive conduct had the overall objective of delaying competition and artificially prolonging the exclusivity of Copaxone (glatiramer acetate) by hindering the market entry and uptake of competing, cheaper copy medicines.

When its patent protecting glatiramer acetate was about to expire, Teva artificially extended Copaxone's patent protection by misusing the European Patent Office's (EPO) rules and procedures on divisional patents. Divisional patents derive from an earlier ‘parent' patent application and share similar content, but may focus on different aspects of the invention and are treated independently when it comes to assessing their validity, the Commission said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight